{"id":"https://openalex.org/W2425839728","doi":null,"title":"\u53d7\u4f53\u9177\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7684\u7b5b\u9009\u53caTKI-31\u6297\u65b0\u751f\u8840\u7ba1\u751f\u6210\u4f5c\u7528\u548c\u673a\u7406\u7684\u7814\u7a76Screening of Receptor lyrosine Kinase Inhibitors and Studies on the Antiangiogenic Effects of the Active Compound TKI-31","display_name":"\u53d7\u4f53\u9177\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7684\u7b5b\u9009\u53caTKI-31\u6297\u65b0\u751f\u8840\u7ba1\u751f\u6210\u4f5c\u7528\u548c\u673a\u7406\u7684\u7814\u7a76Screening of Receptor lyrosine Kinase Inhibitors and Studies on the Antiangiogenic Effects of the Active Compound TKI-31","publication_year":2005,"publication_date":"2005-01-01","ids":{"openalex":"https://openalex.org/W2425839728","mag":"2425839728"},"language":"en","primary_location":{"id":"mag:2425839728","doi":null,"is_oa":false,"landing_page_url":"http://www.irgrid.ac.cn/handle/1471x/615580?mode=full","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"dissertation","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075715774","display_name":"\u949f\u5229","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"\u949f\u5229","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5075715774"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/receptor-tyrosine-kinase-inhibitors","display_name":"receptor tyrosine kinase inhibitors","score":0.9319999814033508},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.7870000004768372},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.734000027179718},{"id":"https://openalex.org/keywords/vegf-signaling","display_name":"VEGF signaling","score":0.7760000228881836},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.4490000009536743},{"id":"https://openalex.org/keywords/endothelial-cell-proliferation","display_name":"endothelial cell proliferation","score":0.9570000171661377},{"id":"https://openalex.org/keywords/endothelial-cell-migration","display_name":"endothelial cell migration","score":0.9879999756813049},{"id":"https://openalex.org/keywords/tube-formation","display_name":"tube formation","score":0.8629999756813049},{"id":"https://openalex.org/keywords/chick-chorioallantoic-membrane","display_name":"chick chorioallantoic membrane","score":0.7639999985694885},{"id":"https://openalex.org/keywords/angiogenesis-inhibitors","display_name":"angiogenesis inhibitors","score":0.5649999976158142},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6340000033378601},{"id":"https://openalex.org/keywords/pdgfrbeta","display_name":"PDGFR\u03b2","score":0.8870000243186951},{"id":"https://openalex.org/keywords/c-kit","display_name":"CD117","score":0.9210000038146973},{"id":"https://openalex.org/keywords/src-kinase","display_name":"Src kinase","score":0.9929999709129333}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5773056745529175},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5436879396438599},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4150570034980774},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3254198431968689},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12499162554740906}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2425839728","doi":null,"is_oa":false,"landing_page_url":"http://www.irgrid.ac.cn/handle/1471x/615580?mode=full","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.6600000262260437,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"},{"score":0.46000000834465027,"display_name":"Partnerships for the goals","id":"https://metadata.un.org/sdg/17"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2011135513","https://openalex.org/W7063206214","https://openalex.org/W2025130323","https://openalex.org/W1173726281","https://openalex.org/W3030016366","https://openalex.org/W1031171588","https://openalex.org/W2280211605","https://openalex.org/W2902242063","https://openalex.org/W2047352105","https://openalex.org/W2092340387"],"abstract_inverted_index":{"\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u5728\u7ec6\u80de\u5185\u7684\u4fe1\u53f7\u8f6c\u5bfc\u901a\u8def\u4e2d\u5360\u636e\u4e86\u5341\u5206\u91cd\u8981\u7684\u5730\u4f4d\uff0c\u5b83\u4eec\u7684\u5f02\u5e38\u8868\u8fbe\u5c06\u5bfc\u81f4\u7ec6\u80de\u751f\u957f\u3001\u589e\u6b96\u3001\u5206\u5316\u3001\u6b7b\u4ea1\u7b49\u4e00\u7cfb\u5217\u8fc7\u7a0b\u53d1\u751f\u7d0a\u4e71\uff0c\u8fdb\u800c\u5bfc\u81f4\u80bf\u7624\u53d1\u751f\u3002\u6b64\u5916\uff0c\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u7684\u5f02\u5e38\u8868\u8fbe\u8fd8\u4e0e\u80bf\u7624\u7684\u4fb5\u88ad\u548c\u8f6c\u79fb\u3001\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u751f\u6210\u53ca\u80bf\u7624\u7684\u5316\u7597\u6297\u6027\u5bc6\u5207\u76f8\u5173\u3002\u56e0\u6b64\uff0c\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u5df1\u6210\u4e3a\u975e\u5e38\u91cd\u8981\u548c\u6709\u4ef7\u503c\u7684\u6297\u80bf\u7624\u9776\u70b9\u3002\u5176\u4e2d\uff0c\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff0f\u53d7\u4f53\uff08VEJ\uff0fVEGFR\uff09\u4ecb\u5bfc\u7684\u4fe1\u53f7\u8f6c\u5bfc\u901a\u8def\u7531\u4e8e\u5728\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u751f\u6210\uff0c\u5b9e\u4f53\u7624\u7684\u6076\u6027\u751f\u957f\u548c\u8f6c\u79fb\u4e2d\u8d77\u7740\u975e\u5e38\u91cd\u8981\u7684\u4f5c\u7528\u800c\u6210\u4e3a\u6297\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u751f\u6210\u7684\u70ed\u70b9\u3002\u8fc4\u4eca\u4e3a\u6b62\uff0c\u5df2\u6709\u5341\u591a\u79cd\u9776\u5411VEGF/VEGFR\u4fe1\u53f7\u8f6c\u5bfc\u7684\u7279\u5f02\u6027\u6297\u4f53\u548c\u5c0f\u5206\u5b50\u6291\u5236\u5242\u8fdb\u5165\u6297\u80bf\u7624\u7684\u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u3002\u5176\u4e2d\uff0c\u9776\u5411VEGF\u7684\u5355\u514b\u9686\u6297\u4f53AvastinTM\u5df2\u88abFDA\u6279\u51c6\u4e0a\u5e02\u3002AvastinTM\u5728\u80bf\u7624\u4e34\u5e8a\u6cbb\u7597\u4e0a\u7684\u6210\u529f\u5e94\u7528\u4e3a\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u751f\u6210\u6291\u5236\u5242\u7684\u5f00\u53d1\u5c55\u793a\u4e86\u5149\u660e\u7684\u524d\u666f\u3002\u4e3a\u8fbe\u5230\u7814\u5236\u5177\u6709\u6211\u56fd\u81ea\u4e3b\u77e5\u8bc6\u4ea7\u6743\u7684\u6297\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u751f\u6210\u5c0f\u5206\u5b50\u6291\u5236\u5242\u7684\u76ee\u7684\uff0c\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u6211\u4eec\u5efa\u7acb\u4e86\u4e0e\u65b0\u751f\u8840\u7ba1\u751f\u6210\u5bc6\u5207\u76f8\u5173\u7684VEGFR2\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7684\u5206\u5b50\u7b5b\u9009\u6a21\u578b\u5e76\u7b5b\u9009\u5f97\u5230\u6d3b\u6027\u5316\u5408\u7269TRI-31\u3002\u7ed3\u5408\u5b9e\u9a8c\u5ba4\u4e2d\u5df2\u7ecf\u5efa\u7acb\u7684VEGFRI\u3001EGFR\u3001PDGFR\u03b2\u3001c-Kit\u3001c-Src\u7b49\u5206\u5b50\u548c\u7ec6\u80de\u7b5b\u9009\u6a21\u578b\uff0c\u5bf9TKI-31\u7684\u751f\u7269\u5b66\u529f\u80fd\u53ca\u5176\u673a\u5236\u8fdb\u884c\u4e86\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u3002\u8fdb\u800c\uff0c\u6211\u4eec\u4ece\u5185\u76ae\u7ec6\u80de\u589e\u6b96\u3001\u8fc1\u79fb\u53ca\u7ba1\u8154\u5f62\u6210\u7b49\u51e0\u4e2a\u65b9\u9762\u7814\u7a76\u4e86TKI-31\u7684\u4f53\u5916\u6297\u65b0\u751f\u8840\u7ba1\u751f\u6210\u7684\u4f5c\u7528\u3002\u7ed3\u679c\u663e\u793a\uff1a\u5728\u4f53\u5916\uff0cTM-31\u5bf9VEGF\u8bf1\u5bfc\u7684\u5185\u76ae\u7ec6\u80de\u589e\u6b96\u5177\u6709\u5f88\u5f3a\u7684\u6291\u5236\u4f5c\u7528\uff1b\u5728\u65e0\u7ec6\u80de\u6bd2\u7684\u5242\u91cf\u4e0b\u77ed\u65f6\u95f4\u5185\u5c31\u80fd\u660e\u663e\u6291\u5236\u5185\u76ae\u7ec6\u80de\u7684\u8fc1\u79fb\u53ca\u7ba1\u8154\u5f62\u6210\u3002\u91c7\u7528CAM\u5b9e\u9a8c\u8bc1\u5b9e\uff0cTKI-31\u5728\u4f53\u5185\u4e5f\u80fd\u660e\u663e\u6291\u5236\u65b0\u751f\u8840\u7ba1\u751f\u6210\u3002\u7efc\u4e0a\u6240\u8ff0\uff0c\u6211\u4eec\u6210\u529f\u5efa\u7acb\u4e86\u7075\u654f\u3001\u7a33\u5b9a\u7684\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176VEGFR2\u6291\u5236\u5242\u5206\u5b50\u6c34\u5e73\u7684\u7b5b\u9009\u6a21\u578b\uff0c\u4e3a\u7814\u5236\u4ee5\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u4e3a\u9776\u70b9\u7684\u65b0\u578b\u6297\u80bf\u7624\u836f\u7269\u5960\u5b9a\u4e86\u826f\u597d\u7684\u57fa\u7840\u3002\u5229\u7528\u5df2\u5efa\u7acb\u7684\u7b5b\u9009\u6a21\u578b\uff0c\u6211\u4eec\u83b7\u5f97\u4e86\u6570\u4e2a\u5177\u6709\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u4f5c\u7528\u7684\u6d3b\u6027\u5316\u5408\u7269\uff0c\u5176\u4e2dTKI-31\u5177\u6709\u5f88\u5f3a\u7684\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u4f5c\u7528\u3001\u6297\u80bf\u7624\u4f5c\u7528\u548c\u65b0\u751f\u8840\u7ba1\u751f\u6210\u6291\u5236\u4f5c\u7528\u3002\u540c\u65f6\uff0c\u673a\u5236\u7814\u7a76\u53d1\u73b0\uff0c\u5176\u5bf9\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u4e0b\u6e38\u4fe1\u53f7\u8f6c\u5bfc\u901a\u8def\u5177\u6709\u660e\u663e\u6291\u5236\u4f5c\u7528\u3002\u8fd9\u4e00\u5316\u5408\u7269\u7684\u6df1\u5165\u7814\u7a76\u5c06\u4e3a\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7684\u8bbe\u8ba1\u63d0\u4f9b\u826f\u597d\u7684\u7ed3\u6784\u57fa\u7840\u548c\u4f5c\u7528\u6a21\u5f0f\u3002":[0]},"counts_by_year":[],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2016-06-24T00:00:00"}